G98-1349 Woody Landscape Plants: Selection and Planting

This NebGuide discusses how to select the right tree or shrub for any location and how to properly plant and care for it. Properly planted and cared for trees and shrubs add beauty, protection, diversity and value to almost any property, whether they are planted in a park, in front of your house, or along a street or highway. Planting is only the first step in the process of maintaining a well kept, desirable landscape. Proper maintenance practices need to be considered and performed on an annual basis to ensure the plant\u27s long term health and vigor. Landscape trees and shrubs are not difficult to plant, but proper species selection and planting techniques are necessary to ensure success. Successful planting also requires a knowledge of growth characteristics, site requirements and intended landscape function

Care of Newly Planted Trees

Landscape trees provide beauty and utility. The care they receive during the first few years after planting is critical. This NebGuide discusses recommended cultural practices for young trees. Many recommendations have changed drastically in recent years in light of new and more thorough research

G94-1195 Care of Newly Planted Trees

Mulching, pruning, watering, wrapping, staking, and fertilizing affect the growth and development of young trees. This NebGuide explains the proper practices of caring for newly planted trees. Landscape trees provide beauty and utility. The care they receive during the first few years after planting is critical. This NebGuide discusses cultural practices that are recommended for young trees. Many recommendations have changed drastically in recent years in light of new and more thorough research

NF93-112 Damaged Trees: How to Select an Arborist or Tree Service

This NebFact offers advice for selecting an arborist or tree service

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label trial evaluating if targeting the immunosuppressive adenosine pathway can enhance the antitumor activity of chemo-immunotherapy. The phase I part included 6 patients with untreated locally-advanced or mTNBC to determine the safety and recommended phase II dose of the anti-CD73 antibody oleclumab in combination with the anti-PD-L1 durvalumab and 12 cycles of weekly carboplatin and paclitaxel. In the phase II part, 127 women were randomized 1:1 to receive chemo-immunotherapy, with (arm A) or without (arm B) oleclumab. The primary endpoint was the clinical benefit rate at week 24, defined as stable disease, partial or complete response per RECIST v1.1. Secondary endpoints included objective response rate, duration of response, survival outcomes (progression-free survival and overall survival), and safety. The trial did not meet its primary endpoint, as the 24-week clinical benefit rate was not significantly improved by adding oleclumab (43% vs. 44%, p = 0.61). Exploratory median progression-free survival was 5.9 months in arm A as compared to 7.0 months in arm B (p = 0.90). The safety profile was manageable in both arms.info:eu-repo/semantics/publishe